Journal Article

Therapeutic challenges in peripheral T-cell lymphoma

Ye, Shili, Yang, Dong-Hua, Yang, Jun, Luo, Junyu, Li, Yanmei, Dong, Qinzuo, Li, Xiang, Jia, Lu, Li, Yuejin, Luan, Yunpeng, Luan, Yunqi

2024

Overview

Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced, and a significant number of patients are diagnosed with advanced stages of the disease. Unfortunately, the development of drug resistance in tumors leads to relapsed or refractory peripheral T-Cell Lymphomas (r/r PTCL), resulting in highly unsatisfactory treatment outcomes for these patients. This review provides an overview of potential mechanisms contributing to PTCL treatment resistance, encompassing aspects such as tumor heterogeneity, tumor microenvironment, and abnormal signaling pathways in PTCL development. The existing drugs aimed at overcoming PTCL resistance and their potential resistance mechanisms are also discussed. Furthermore, a summary of ongoing clinical trials related to PTCL is presented, with the aim of aiding clinicians in making informed treatment decisions.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: ALCL / Aluminum compounds / Biomedical and Life Sciences / Biomedicine / Cancer Research / Care and treatment / Chemotherapy / Chromosomes / Classification / Clinical trials / Development and progression / Disease / Drug development / Drug resistance / Gene expression / Health aspects / Leukemia / Lymphocytes / Lymphocytes B / Lymphocytes T / Lymphoma / Malignancy / Medical prognosis / Mutation / NHL / Non-Hodgkin's lymphomas / Oncology / Patients / PTCL / Review / T cells / T-ALL / T-cell lymphoma / Treatment resistance / Tumor microenvironment / Tumors / Vincristine